 |
Welcome to Genafor − Open Services for Medical Research |
|
Slides are available online as image files. Please write to info@genafor.org if we should send you a PDF file.
| Zeit | Vorträge |
09:30 - 12:00 | Chair: Ulrich Spengler, Michael Roggendorf |
| Phenotypic assays for HBV resistance tests |
| HBV Testing for drug resistance and resistance interpretation |
| HIV-GRADE HBV-Tool |
| Hepatitis B -Resistencemanagementin the clinical setting |
| Escape mutations in occult and reactivated hepatitisB virusinfection |
| |
| HBV Aktuelle Therapieleitlinien, Resistenzproblematik und Erfahrungen aus der Praxis |
| HIV-Coinfections, HIV-HBV/HCV infections in RESINA-patients |
| Impact of the Variability of the Hepatitis-B-Virus surface Antigen (sAg) on Detection in different Analytic Systems |
12:00 - 12:20 | Laudatio Lutz Gürtler |
12:20 - 13:30 | Chair: Eva Wolf, Lutz Gürtler |
| The ARCA database, Features and perspectives |
| New Drugs/Targets - New Challenges |
| Guiding Treatment Selection: past, present, and futureArevirMeeting |
| Clinical application / relevance |
14:30 - 14:45 | Chair: Rolf Kaiser |
| Modified RNA (MRT) |
14:45 - 16:45 | Chair: Herbert Pfister, Dieter Häussinger |
| Analysis of resistance mutations of HI-Virus |
| EuResist |
| Establishing a resistance database within the Competence Network for HIV/AIDS |
| Rega Institute for Medical Research |
| RegaDB |
17:00 - 19:00 | Chair: Bernd Kupfer, Martin Däumer |
| Integrase Inhibitoren |
| Analysis of IntegraseInhibitor (INI) resistance in ART-and INI-naïve and -experienced patients |
| geno2pheno [integrase] |
| HIV Gag under multiple pressure - protease inhibitors, immune system and replication capacity |
| Updated virtual Phenotype-LM approach and Clinical Cut-Offs for the virco® TYPE HIV-1 Resistance Analysis |
| Zeit | Vorträge |
09:00 - 09:30 | Selbsthilfegruppe HIV/ HCV |
| PrisMed eine wisssenschaftsorientierte Selbsthilfegruppe für HIV/HCV, Resistenzen und AD(H)S |
09:30 - 13:30 | Chair: Gerd Fätkenheuer, Eva Wolf |
| CCR5 Antagonists In Clinical Practice |
| X-TrackC: a "genosorting"method for highly sensitive determination of HIV co-receptor tropism |
| HIV HIV-1 tropism prediction |
| V3 Loop Sequence Space Analysis |
| Evolution of HIV geno-and phenotypes during anti-retroviral therapy |
| Genotypic analysis of coreceptor usage. New developments and applications for geno2pheno [coreceptor] |
| Genotypic Tropism testing in Germany,
Comparison of TROFILE® and seven genotypic interpretation approaches |
| Multicentre study to evaluate the relation study between the efficacy of treatment with the
CCR5 inhibitor Maraviroc and HIV-1 co-receptor tropism as determined by V3 loop sequencing |
| Minorities: "ultra deep sequencing"of HIV V3 |
| Coreceptor Prediction Consensus |
14:30 - 17:00 | Chair: Hans-Wilhem Doerr, Thomas Harrer |
| New graphical user interface for geno2pheno resistance |
| Arevir Update: MPI Informatics |
| HAART in Patients with Primary HIV Drug Resistance: The RESINA Study |
| Influence of the K103N minor variants in therapy-naïve HIV-1 infected patients on clinicaloutcome |
17:00 - 17:45 | Chair: Mark Oette |
| Transmission of resistant HIV in patients with a known date of infection |
| Co-receptorusageas a marker for specific HIV diagnostics with high sensitivity |
| Co-Receptor usage as marker for specific HIV diagnostics with high sensitivity |
| EuResist: An integrated system for management of antiretroviral drug resistance |
17:45 - 18:30 | Chair: Stefan Esser, Heribert Knechten |
| HLA and Drug Resistance |
| Correlations between transmitted HIV-1 drug resistance mutations and the HLA of therapy-naive HIV-patients |
Download Programm (PDF)